The price hikes come even as the Trump administration pressures pharmaceutical companies to lower costs for patients.

Savings for Part D and Advantage enrollees depend largely on which plan they’re enrolled in, as not all plans are the same.

Several common drugs will be cheaper next year under Medicare, from weight-loss drug Ozempic to breast-cancer medication Ibrance, according to the Centers for Medicare & Medicaid Services (CMS).

Big savings are coming in 2026. See the list of the first 10 drugs with prices negotiated by Medicare, including Eliquis, ...

CMS released a preliminary list of 101 generic drugs for its Medicare $2 Drug List Model, which aims to cap out-of-pocket costs at $2 per month for select medications. The initial list includes common ...

Drugs currently shortage FDA total 75 as of Dec. 30, down from 194 in June, mainly hospital injectables and acute care meds.

In Nation Healthcare Security Administration’s (NHSA’s) announcement for the 2025 NRDL, the government’s support for ...

New analysis makes clear that the Inflation Reduction Act’s inflation rebates should extend to the commercial market. To combat excessive pharmaceutical price hikes, the Inflation Reduction Act ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "Not only are direct-to-consumer offerings more convenient, ...